82 results about "Recombinant GH" patented technology

The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose- related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.

Novel fluorinated synthetic analogs of hGH-RH(1-30)NH₂ that inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers through a direct effect on the cancer cells, and to therapeutic compositions containing these novel peptides and their use.

The invention discloses recombinant oral protein TAT-GH of tilapia, a preparation method for the recombinant oral protein TAT-GH and application of the recombinant oral protein TAT-GH. The method comprises the following steps of: extracting total messenger ribonucleic acid (mRNA) from a pituitary gland of male tilapia, performing reverse transcription-polymerase chain reaction (RT-PCR) to obtain complementary deoxyribonucleic acid (cDNA), performing PCR amplification to obtain a growth hormone (GH) gene of the tilapia, and amplifying a TAT-GH gene by a PCR overlap extension method; constructing a recombinant plasmid pET-32a(+)-TAT-GH; and transforming Escherichia coli BL21 (DE3) by using the recombinant plasmid pET-32a(+)-TAT-GH, efficiently expressing fusion protein TAT-GH in the form of an inclusion body under the induction of isopropyl thiogalactoside (IPTG), and purifying and renaturing to obtain active protein. The protein can effectively promote the growth and development of fries of the tilapia after being fed to the fries of the tilapia.

The present invention belongs to the field of animal gene engineering, and is especially the cloning and polymorphism application of goat's growth hormone (GH) gene. The present invention features that two DNA sequences of goat's GH gene as shown is obtained through cloning and two base mutations affecting goat's growth characters are detected. The present invention discloses two goat's GH gene sequences and two base mutational sites affecting goat's growth characters. The present invention also discloses the preparation process and application of the said genes, and provides new molecular markers for the auxiliary selection of goat's growth characters.

The present application disclosed a method for preparing a sterile transgenic fish, comprising constructing antisense RNA expression vector of salmon-type gonadotropin-releasing hormone, introducing the recombinant DNA fragment into carp oosperm by microinjection, and screening the sterile transgenic fish by Polymerase Chain Reaction and radioimmunoassay, wherein the expression vector comprising a promoter of carp beta actin (β-actin) gene, a complementary DNA fragment of antisense salmon-type gonadotropin-releasing hormone (sGnRH) gene from carp with 323 bp as a target gene comprising sGnRH decapeptide, the coding region of gonadotropin-releasing hormone associated peptide and 3′ non-coding sequence, and 3′ flanking sequence of grass carp growth hormone gene as a stop sequence. The method of the present invention is easy and convenient for operation which provides a basis for providing a technical platform of general applicability for solving the hereditary and ecological safety problems of transgenic fishes.

The invention relates to a gene recombinant human growth hormone modification substance for treating microsoma caused by children's endogenous recombinant human growth hormone deficiency or insufficiency and for surgeries for injuries and serious burns and subsequent treatment, particularly a preparation method of a polyethyleneglycol (PEG) modification substance of the growth hormone. The invention aims to provide a preparation method of a recombinant human growth hormone, which is higher in expression level and convenient for operation, can enhance the purity and activity of the effective drug and can enhance the purity and activity of the product on the premise of not increasing the cost, thereby enhancing the activity of the drug. The invention also aims to provide a preparation method of the recombinant human growth hormone PEGylation modification substance. According to the method, the PEGylation is utilized to modify the drug, so that the PEG and human growth hormone are connected through covalence, thereby prolonging the half life of the drug and lowering the toxic or side effect of the drug protein.

The invention discloses a [beta]-actin promoter, a growth hormone gene and a 3<,>-untranslated region (3<,> UTR) of pseudobagrus fulvidraco richardson, and a pseudobagrus-fulvidraco-richardson-origin transgenic vector constructed with the [beta]-actin promoter, the growth hormone gene, and the 3<,> UTR as elements. According to the invention, sequences of the pseudobagrus fulvidraco richardson [beta]-actin promoter, sequences of exon 1, sequences of partial exon 2, amino acid data-encoding sequences of the growth hormone gene, and sequences of the 3<,> UTR are acquired. The pseudobagrus-fulvidraco-richardson-origin transgenic vector is constructed with the obtained [beta]-actin promoter, the obtained growth hormone gene, and the obtained 3<,> UTR as elements. According to the invention, the transgenic vector is constructed through driving the growth hormone gene expression of pseudobagrus fulvidraco richardson by the [beta]-actin promoter of its own. With the technical scheme of the present invention, biosafety problems of faced by transgenic fish can be effectively avoided. Therefore, the invention has great practical significance and application prospects in the genetic breeding and artificial fertilizing of pseudobagrus fulvidraco richardson.

The invention belongs to the technical field of functional study of polypeptide and discloses a polypeptide PP1 capable of promoting expression of growth hormone of tilapia mossambica and application thereof. The amino acid sequence of the polypeptide PP1 is YPVPLENPGPADPAEEL. By intraperitoneal injection of tilapia mossambica by a solution of the polypeptide PP1, results display that the PP1 can obviously promote the expression level of growth hormone in hypophysis cerebri of tilapia mossambica and has physiological activity. The polypeptide PP1 disclosed by the invention can be used for preparing an oral preparation for improving GHmRNA expression of hypophysis cerebri or fish offspring seed growth promoters or additives.

The invention discloses a quantitative detection kit for growth hormone. The quantitative detection kit comprises an experimental buffer solution, concentrated washing liquor, an enhancement solution, a coated plate, a standard product, a quality control product and a marker, wherein the enhancement solution is prepared from 1 to 5 mg/L of beta-naphthoyltrifluoroacetone, 15 to 30 mg/L of tri-n-octylphosphine oxide and a third buffer solution; the coated plate is prepared from coating liquid, confining liquid and a reaction plate; the coating liquid is prepared from 1 to 10 ppm of Proclin300, a fourth buffer solution and 1 to 10 [mu]g/ml of a growth hormone monoclonal antibody; the confining liquid is prepared from 1.0 to 10.0 g/L of trehalose, bovine serum albumin with the mass volume ratio of 0.4 to 0.6 percent and the fourth buffer solution; the standard quality and the quality control product are filter paper dried blood pieces; the filter paper dried blood pieces comprise mixtures with 8 concentrations; the mixtures comprise red blood cells, de-hormone negative serum mixed matrixes and the growth hormone; and the marker is prepared from the growth hormone monoclonal antibody and a lanthanide ion chelate according to (1: 1) to (1: 6) m/m. The invention further discloses a preparation method of the kit. The kit disclosed by the invention can ensure that a detection result is highly consistent with a detection result of a serum sample.

The invention discloses a recombinant pig growth hormone and a preparation method and application thereof. The preparation method comprises the following steps of: inserting a polynucleotide sequencecontaining a plurality of pig growth hormone full-length sequences into a pichia pastoris expression vector to obtain a recombinant plasmid; introducing the recombinant plasmid into a pichia pastoriscompetent cell to construct a recombinant engineering bacterium; and performing fermentation expression and protein purification on the recombinant engineering bacterium to obtain a target protein, namely the recombinant pig growth hormone. The recombinant pig growth hormone can be applied as a pig feed additive. The recombinant pig growth hormone has the advantages that the protein molecular weight is increased by adopting a multi-linkage mode, so that the problem that the hormone is digested in the stomach and loses functions is solved; meanwhile, a plurality of repeated fragments exist, sothat the problem of short half-life period can be well solved; and in addition, the recombinant pig growth hormone is produced by adopting a recombination mode, is simpler and lower in cost compared with an extraction method, and can be widely applied as the feed additive.

The invention provides a coded sequence of an rhFSH and a method for producing the rhFSH as well as an expressive carrier and a host cell used for the method. A pET system is adopted to express the FSH for the first time, a cell strain with the expression in a high level is obtained by transfecting CHO engineering cells; the high protein expressive rate is obtained by controlling the culture condition; on the base, a large amount of groping and researching of the purification of the rhFSH of the secretion expression are realized to obtain a set of FSH purifying method. The method is adopted to obtain the rhFSH with high yield and high grade of purity and can satisfy the clinical requirements. The coded sequence and method of the invention can obtain the rhFSH purified product with high efficiency, simplicity and low cost.

The invention belongs to the technical field of research on functions of polypeptides and particularly discloses a polypeptide PP2 capable of promoting the expression of a growth hormone (GH) of tilapia and an application of the polypeptide PP2. Polypeptide PP2 has an amino acid sequence of PVKPENPGEDAPAEELAK. After tilapia is subjected to intraperitoneal injection by virtue of a polypeptide PP2 lysate, results show that PP2 can significantly promote the expression level of the growth hormone in tilapia pituitary and has physiological activity. By the polypeptide PP2 disclosed by the invention, an oral preparation for increasing expression of GH mRNA in the pituitary or a growth promoter or an additive for fish fries can be prepared.

The invention discloses a cynoglossus semilaevis GnIH gene, two encoded mature polypeptides and application thereof, and belongs to the field of molecular biologics. The cynoglossus semilaevis GnIH gene is a gene segment which is prepared from cynoglossus semilaevis brain tissue total RNA (Ribonucleic Acid) as a template by using a RT-PCR (Reverse Transcription-Polymerase Chain Reaction) and RACE (Rapid Amplification of Complementary Deoxyribonucleic Acid Ends) method and has full-length cDNA sequences of a cynoglossus semilaevis gonadotropin-inhibitory hormone gene, and through sequence comparison and analysis, two mature polypeptides encoded by using the gene are obtained. The invention further studies the regulation and control functions of the two mature polypeptides encoded by using the GnIH gene upon secretion of luteinizing hormone (LH) and growth hormone (GH) of cynoglossus semilaevis. The invention sets a foundation for developing novel procreation regulation inhibitors with GnIH as a main component.

The invention discloses recombinant human growth hormone and the application thereof in promoting follicular development, belongs to the field of protein drugs, and relates to growth hormone (GH).The recombinant human growth hormone is suitable for promoting follicular development and can increase the rate of pregnancy.The invention further relates to a long-acting pharmaceutic preparation of GH and the application thereof.

The present invention is directed generally to recombinant methods for making a desired polypeptide. These method(s) yield a polypeptide product containing reduced levels of isoform impurities thereof. In particular, the present invention is directed to (1) a recombinant method for preparing growth hormone with reduced isoform impurities thereof and (2) a recombinant method for preparing a growth hormone antagonist, such as pegvisomant, and its protein intermediate, also having reduced isoform impurities thereof. More specifically, the isoform impurities that are decreased by methods of the present invention are the trisulfide and des-phe isoform impurities of growth hormone and growth hormone antagonist (or its intermediate), respectively.

The invention provides a growth hormone fusion protein and application thereof. The fusion protein comprises an Fc mutant, the mutant comprises a first peptide chain, and compared with a wild type IgG4 Fc fragment, the first peptide chain 1) has mutation of the following sites: at least one of the 234 site, the 235 site, the 298 site, the 299 site and the 300 site, and the second peptide chain 2) has mutation of the following sites: at least one of the 234 site, the 235 site, the 298 site, the 299 site and the 300 site; or the 231st to 239th sites; or 2) compared with a wild type IgG1Fc fragment, the IgG1Fc fragment has mutation of the following sites: 228-239 sites, and/or at least one of 268 site, 296 site, 330 site and 331 site. The fusion protein has high binding activity with a human growth hormone receptor, ADCC and CDC effects can be eliminated, Nb2-11 cell proliferation is promoted, and therefore human growth hormone abnormality related diseases are effectively treated or prevented.